Epitalon FDA Approval History

Print or save as PDFOpens the printable question sheet and your print dialog. No sign-up.

Has epitalon ever been FDA approved?

No, and it is not part of anyone else's approved product either. In the briefing document prepared for its July 2026 advisory committee meeting, FDA wrote that epitalon is not an FDA-approved drug and is not a component of one [1]. The same review found no USP or National Formulary monograph, no entry in the European or Japanese pharmacopeias, and no approved product in Canada, Australia, the UK, Belgium, Ireland, France, Norway, Germany, Spain or Italy, nor any authorization by the European Medicines Agency [1].

Compounded epitalon is not approved either: FDA does not verify the safety, effectiveness or quality of compounded drugs before they are marketed [7].

The 2010 orphan designation and its 2016 withdrawal

Orphan drug designation is a status FDA grants to encourage development of drugs for rare diseases. It is not a marketing approval and it does not establish that a drug works.

Epitalon received an orphan drug designation for retinitis pigmentosa on September 2, 2010. The designation was withdrawn or revoked on January 6, 2016 [1].

What happened in 2026

FDA staff reviewed epitalon for one nominated use: insomnia. They proposed that neither epitalon free base nor epitalon acetate be added to the list of bulk substances that may be used in compounding, citing that it is not well characterized, has limited historical use, has no evidence of effectiveness for insomnia and no clinical safety data, carries an immunogenicity concern for subcutaneous injection, and that many FDA-approved insomnia drugs already exist [1]. The other nominated uses, such as anti-aging and telomere lengthening, were not evaluated for lack of information [1]. The nominated products were 10 mg/mL and 3,000 microgram/mL subcutaneous injections [1].

The Pharmacy Compounding Advisory Committee took up epitalon on July 24, 2026 and voted in favor of adding it to the bulks list, against the staff recommendation [5][6]. Advisory committee recommendations are non-binding: FDA generally follows them but is not legally bound to [5]. The vote did not put epitalon on any list, and adding a substance takes formal rulemaking [6].

On October 28, 2026, HHS filed a draft enforcement-discretion policy for compounding with six peptides: BPC-157, epitalon, KPV, MOTS-c, Semax and TB-500 (Federal Register document 2026-22192, publication scheduled for October 30, 2026, comments due two weeks after publication) [6][8]. For epitalon it covers the acetate form, given by subcutaneous or intramuscular injection in intermittent courses. HHS says it 'does not intend to take enforcement action' against a state-licensed pharmacy, federal facility or licensed physician compounding with it if the conditions are met, such as a single active ingredient, a patient-specific prescription, an FDA-registered manufacturer with a certificate of analysis, and a label reading 'This is a compounded drug product. Not for resale.' [6][8]

The notice says it does not establish any rights for any person and is not binding on HHS or the public, and HHS may revisit it, for example if a safety signal or a product quality issue arises [6]. It is not an approval and does not put epitalon on any list [6].

Is epitalon on FDA's compounding lists?

It appears in none of the three categories on FDA's list for state-licensed pharmacies and physicians (updated May 14, 2026), and it is not on FDA's separate list for outsourcing facilities (updated March 21, 2025) [2][3][4]. The policy under which FDA generally does not act against compounders of category 1 substances therefore does not cover it [4].

Epitalon does appear on a different FDA page: the table of bulk substances previously in category 2 whose nominators later withdrew them, in content dated April 22, 2026 [9]. FDA's stated concern was that it 'has not identified safety-related information regarding epitalon for the proposed route of administration', so it lacks enough information to know whether the drug would cause harm; injectable peptides may also carry immunogenicity risk from aggregation and impurities [9]. Removal from category 2 was not a finding that epitalon is safe [9].

Who sells epitalon, and what has been found?

A 2015 laboratory analysis identified epitalon in two illegal pharmaceutical preparations sold for cancer, old age and retinitis pigmentosa [10]. A Kentucky pharmacy was reported by the US Attorney's office to have compounded and distributed epitalon products between October 25, 2018 and April 1, 2020 [1]. In its 2026 review FDA found no pharmacy that compounds epitalon and no outsourcing facility that reports it [1]. It is sold online as research-use-only vials of 10 mg to 50 mg, as capsules and as oral sprays, and is promoted as an anti-aging peptide that lengthens telomeres [1].

What does the human evidence look like?

FDA's review found three human studies of epitalon: two of a sublingual formulation in night-shift workers and one of an injection beside the eye in retinitis pigmentosa. None was in insomnia, and FDA found no clinical study that assessed epitalon's safety [1].

One sublingual study enrolled 75 healthy women aged 40 to 50, most of them night-shift workers; 40 had low melatonin output and were split into two groups of 20 [1]. A spray delivering about 0.5 mg per day, or placebo, was given for 20 days [1]. Urinary 6-sulfatoxymelatonin rose about 1.7-fold with epitalon and did not change with placebo, and 83% versus 25% were described as improved in mood and physical condition [1]. No sleep outcomes were measured, blinding was not specified, and the study was short and small [1].

The retinitis pigmentosa study, published in 2002, reported a 'positive clinical effect in 90% of the cases' in patients with degenerative retinal lesions; the abstract gives no sample size, raw outcome counts or detailed study design [11]. It is an older controlled study and has not been replicated as a modern randomized trial [11][12]. No adequately powered randomized trial has since established efficacy [12].

The telomere finding comes from cell culture. Adding epitalon to telomerase-negative human fetal fibroblast cultures induced the catalytic subunit of telomerase, telomerase activity and telomere elongation [13]. That is a laboratory result, not a measured effect in people [13].

FDA warned that because epitalon activates telomerase and lengthens telomeres, and longer telomeres are generally linked to higher cancer risk, it has a mechanistic potential to be carcinogenic [1]. Its mouse studies of cancer and chromosome damage were too limited to show safety: one fixed dose, female mice only, short exposure [1].

A search of FDA's adverse-event database through December 8, 2025 and of its food and supplement complaint system through December 5, 2025 retrieved no epitalon reports, and one small study gave no safety data [1]. A Russian-language abstract stating 'no side effects' gave no dose, route or number of people [1]. FDA concluded there are no clinical data supporting epitalon's safety and raised an immunogenicity concern for subcutaneous injection [1]. FDA also found no pharmacokinetic data [1].

A 2026 narrative review by Jain et al. in the International Journal of Molecular Sciences, searching through September 22, 2026, concluded that human evidence is limited to small physiological or biomarker studies and an older controlled study in retinitis pigmentosa, that no adequately powered randomized trial has established efficacy, and that pharmacokinetic, dose-ranging and long-term safety data are inadequate. It called epitalon 'biologically active but clinically unproven' [12].

Is there an approved dose?

Epitalon has no approved dose or FDA-approved dosing label [1]. Websites FDA reviewed suggest 5 mg to 10 mg a day by subcutaneous injection or orally, in cycles, with one site suggesting every four months; that is marketing, not evidence [1]. The human studies FDA found used a sublingual spray delivering about 0.5 mg a day for 20 days and a parabulbar injection, given beside the eye, for retinitis pigmentosa [1].

What about other countries and sport?

Outside the US, FDA's review found no approved epitalon product in the countries listed above and no European Medicines Agency authorization [1]. Epithalamin, the pineal extract epitalon was designed from, is treated by FDA as a different substance, so studies of epithalamin are not studies of epitalon [1].

Epitalon is not named in WADA's 2026 Prohibited List or in the 2027 list in its tracked-changes version dated August 26, 2026 [14][15]. Class S0 of the list prohibits at all times any pharmacological substance with no current approval by any governmental regulatory health authority for human therapeutic use, and it names BPC-157 only as an example, with the wording 'including but not limited to' [14][15]. Neither list says whether class S0 applies to epitalon [14][15].

What would change epitalon's status?

Adding epitalon to FDA's bulks list would allow compounding under the conditions FDA sets, and that takes notice-and-comment rulemaking [6]. That would still not be a drug approval. FDA found no pharmacokinetic data and no clinical study assessing safety, and a 2026 review found dose-ranging and long-term safety data inadequate [1][12].